ReviveMed Inc., a Cambridge, MA-based developer of an AI-driven metabolomic platform for drug discovery, closed a $1.5m seed funding round.
The round was led by Rivas Capital with participation from TechU, Team Builder Ventures, and WorldQuant Ventures. In connection with the financing, Carlos Gonzalez, the founder of Rivas Capital, will join the ReviveMed board of directors.
The company will use the funds to advance its artificial intelligence (AI)-driven platform.
Led by Dr. Leila Pirhaji, Founder and CEO, and Prof. Ernest Fraenkel of MIT, co-founder and board member, ReviveMed is advancing an AI-driven metabolomic platform that leverages metabolomics data for drug discovery and development. The platform enables fast, high-throughput, and identification of metabolites, and translates these data into therapeutic insights.
The company’s initial internal discovery program is in metabolic diseases and focused specifically on non-alcohol fatty liver disease (NASH).